← Gordon B. Mills

Papers by Gordon B. Mills

Page 2 · newest first

51. Supplementary Video S1 from Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas2024
52. Supplementary Video S1 from Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas2024
53. Data from Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas2024
54. Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource2024
55. Supplementary Video S1 from “Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource2024
56. Cyclin E1/CDK2 Activation Defines a Key Vulnerability to WEE1 Kinase Inhibition in Gynecological Cancers2024
57. Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 ExpressionJCO Precision Oncology · 2024
58. Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Journal of Clinical Oncology · 2024
59. Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities.Journal of Clinical Oncology · 2024
60. C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancerNature Communications · 2024
61. Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages2024
62. COEXIST: Coordinated single-cell integration of serial multiplexed tissue images2024
63. Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancerCancer Research · 2024
64. Enhancing anticancer activity of macrophages through rational drug combinationsJournal of Clinical Investigation · 2024
65. Abstract CT203: Multi-omic analysis of serial biopsies to inform biomarkers of sensitivity to olaparib and durvalumab in patients with metastatic BRCA-wildtype triple negative breast cancer (mTNBC)Cancer Research · 2024
66. Abstract LB414: Novel ALK/PIK3CA cooperativity in head and neck squamous cell carcinoma (HNSCC) progressionCancer Research · 2024
67. Abstract LB247: TCPAplus: An LLM-empowered chatbot for analyzing a large protein expression atlas of human cancersCancer Research · 2024
68. MIM-CyCIF: masked imaging modeling for enhancing cyclic immunofluorescence (CyCIF) with panel reduction and imputationCommunications Biology · 2024
69. Abstract 5280: Minimizes T cells DNA damage induced by PARP inhibitors and enhances its anti-tumor efficacyCancer Research · 2024
70. Abstract 2499: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to targeting RAS signalingCancer Research · 2024
71. Abstract 2504: Determining tumour homologous recombination repair status in PDX and clinical samples using automated RAD51 scoringCancer Research · 2024
72. Abstract 3997: PARP inhibitors plus anlotinib as bridging therapy for TGFβ-insensitive CAR-T cell therapy targeting MSLN and CD19 in advanced ovarian cancerCancer Research · 2024
73. Abstract 5279: Sequential treatment with PARPi and WEE1i minimizes T cell DNA damage and enhances its immune responseCancer Research · 2024
74. Abstract 583: Spatiotemporal analyses of longitudinal specimens reveal mechanisms of response and resistance to immune checkpoint blockade in metastatic melanomaCancer Research · 2024
75. Abstract 3344: Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA binding proteinsCancer Research · 2024
76. Abstract A064: Study of molecular pathways involved in the development of ovarian cancer brain metastasesCancer Research · 2024
77. Graph Structured Neural Networks for Perturbation Biology2024
78. Dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit2024
79. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML2024
80. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerScientific Reports · 2023
81. Accessible high-throughput single-cell whole-genome sequencing with paired chromatin accessibilityCell Reports Methods · 2023
82. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteinsCell Reports Medicine · 2023
83. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunityCell Reports · 2023
84. Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers2023
85. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast CancerNature Communications · 2023
86. Explainable Machine Learning Reveals the Role of the Breast Tumor Microenvironment in Neoadjuvant Chemotherapy Outcome2023
87. Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesiclesCommunications Biology · 2023
88. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancerCell Death and Disease · 2023
89. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesBreast Cancer Research and Treatment · 2023
90. Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant statesCell Death Discovery · 2023
91. Actionability classification of variants of unknown significance correlates with functional effectnpj Precision Oncology · 2023
92. Serial multiomic analysis in advanced breast cancer: A novel platform to inform therapeutic decisions.Journal of Clinical Oncology · 2023
93. The Breast Cancer Proteome and Precision OncologyCold Spring Harbor Perspectives in Medicine · 2023
94. Systematic Pan-cancer Functional Inference and Validation of Hyper, Hypo and Neomorphic Mutations2023
95. Abstract 4916: Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancerCancer Research · 2023
96. Abstract 6618: Longitudinal, multimodal profiling of metastatic ER+ breast cancer on CDK4/6 inhibitor therapyCancer Research · 2023
97. Supplementary Figures 1-12, Tables 5-8, Methods from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer2023
98. Supplementary Figures 1-12, Tables 5-8, Methods from ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer2023
99. Data from Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models2023
100. Supplementary Methods and Figure Legend from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP12023